A Phase Ia/Ib, First-In-Human, Dose-Escalation Study Evaluating The Safety, Tolerability, And Efficacy Of Ios-1002, A Lilrb1, Lilrb2, And Kir3Dl1 Targeting Hla-Derived Fusion Protein Administered Alone Or In Combination With A Pd-1 Antibody In Patients With Advanced Solid Tumors
IOS-1002
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase Ia/Ib, First-In-Human, Dose-Escalation Study Evaluating The Safety, Tolerability, And Efficacy Of Ios-1002, A Lilrb1, Lilrb2, And Kir3Dl1 Targeting Hla-Derived Fusion Protein Administered Alone Or In Combination With A Pd-1 Antibody In Patients With Advanced Solid Tumors ### Output: IOS-1002